Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.66 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5405414 | 0.98 | CHRNB2 (0.64) | CHRNB2CHRNA4LMNAHPGDTSHR | |
| SCHEMBL8901225 | 0.92 | CHRNB2 (0.64) | CHRNB2CHRNA4LMNAHPGDTSHR | |
| Hydrochloric Acid SCHEMBL3037290 | 0.90 | CHRNB2 (0.62) | CHRNB2CHRNA4LMNAHPGDTSHR | |
| SCHEMBL5149377 | 0.90 | CHRNB2 (0.62) | CHRNB2CHRNA4LMNAHPGDTSHR | |
| Diethylamine SCHEMBL27884425 | 0.90 | CHRNB2 (0.59) | CHRNB2CHRNA4LMNAHPGDLTA4H | |
| SCHEMBL15498199 | 0.90 | CHRNB2 (0.73) | CHRNB2CHRNA4LMNAHPGDTSHR | |
| SCHEMBL4343371 | 0.89 | CHRNB2 (0.61) | CHRNB2CHRNA4LMNAHPGDTSHR | |
| SCHEMBL16943480 | 0.87 | CHRNB2 (0.66) | CHRNB2CHRNA4LMNAHPGDTSHR | |
| SCHEMBL14028449 | 0.86 | CHRNB2 (0.69) | CHRNB2CHRNA4LMNAHPGDTSHR | |
| SCHEMBL11307294 | 0.85 | CHRNB2 (0.64) | CHRNB2CHRNA4LMNAHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0999823-A1 | COMPOSITION FOR DYEING KERATIN FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2000-05-17 | — | — | EP | claimed |
| WO-1999020235-A1 | COMPOSITION FOR DYEING KERATIN FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 1999-04-29 | — | — | WO | claimed |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| EP-1067928-A4 | METHODS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1067928-A1 | METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999051228-A1 | METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | CCNO, PTGDR, CCNE1 | CHRNB2 4737/4885CHRNA4 4804/4885LMNA 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.